Results with clinical significance

The presence and pattern of gene mutations in a known or suspected hematologic neoplasm can provide critical diagnostic, prognostic, and therapeutic information for physicians. While many hematologic neoplasms show morphologic or phenotypic similarities, most harbor a distinct composition of somatic gene mutations. In addition, many myeloid neoplasms lack a clonal bone marrow cytogenetic finding at diagnosis (normal karyotype) but can be better characterized with the aid of a sufficiently comprehensive gene mutation profile.

At Mayo Clinic Laboratories, we strive to provide the highest quality molecular services available to complement your clinical practice by offering three myeloid gene panels, including a comprehensive, 42-gene OncoHeme panel and two acute myeloid leukemia (AML) focused subpanels. In addition, we offer comprehensive fluorescence in situ hybridization (FISH) panels.

Next-generation sequencing for acute myeloid leukemias

Our next-generation sequencing testing for AML and myelodysplastic syndromes (MDS) offers both comprehensive and focused approaches to testing. Flexible ordering includes 4-gene, 11-gene, and 42-gene panels to meet your patients’ specific needs, with the option of add-on (reflex) analysis for the additional genes in the 42-gene panel if a smaller panel was ordered initially. The comprehensive, 42-gene panel follows World Health Organization and National Comprehensive Cancer Network guidelines for genes of clinical significance. Diagnostic, prognostic, therapeutic, or germline, our test has your patients covered.

NGSHM | OncoHeme Next-Generation Sequencing for Myeloid Neoplasms, Varies

NGAML | Next-Generation Sequencing, Acute Myeloid Leukemia, 11-Gene Panel, Varies

NGAMT | Next-Generation Sequencing Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Varies